Biogen (BIIB) Revenue — Quarter Ended Dec 31, 2023
Revenue declined in the reporting quarter compared to the prior quarter. The decrease also extended versus the same quarter one year earlier.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue declined in the reporting quarter compared to the prior quarter. The decrease also extended versus the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.4B
Revenue reported for this quarter.
Quarter-over-quarter
-5.7%
Change from the immediately preceding quarter.
Year-over-year
-6.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $2.5B | -4.9% |
| Jun 30, 2023 | $2.5B | -5.1% |
| Sep 30, 2023 | $2.5B | +0.9% |
| Dec 31, 2023 | $2.4B | -6.2% |
Revenue performance
The reported revenue moved lower from the immediately preceding quarter. This downward trend was consistent with the year-over-year comparison.
Quarterly comparison
Compared to the prior quarter, revenue was lower. The same quarter a year ago also showed a higher revenue figure than the current period.
What to watch
The filing context notes a decrease in cash and marketable securities largely due to an acquisition, which may affect future liquidity.